WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com

WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

NHSA Seeks Public Input on 2025 Drug Reimbursement and Innovation List Reform ... The NHSA has released for public consultation a set of draft policy documents outlining the 2025 adjustment framework for the NRDL and a separate list for commercial heal...
(7/1/2025)

Analysing Key Trends In China's Patent-linkage... (7/12/2025)

China's Rising Biotechnology Sector: Friend or... (7/10/2025)

As Chinese-developed Drugs Draw U.S. Interest,... (7/8/2025)

FDA's Crackdown and China's Dealmaking: Warnin... (7/2/2025)

Medical Advances Soar With APAC's Clinical Tri... (7/2/2025)

Tracking the Crossroads of Policy, Innovation,... (7/1/2025)

BeOne Launches Phase III Trial Comparing Subcu... (7/1/2025)

China Launches Landmark Measures to Boost Inno... (7/1/2025)

Analyzing Key Trends in China's Patent-Linkage... (6/27/2025)

Fresh Antitrust Guidelines to Address Pharmace... (6/27/2025)

Breaking the Boundaries: A New Map of Physicia... (6/25/2025)

Structuring Cross Border China Biotech 'NewCo'... (6/19/2025)

Recent Executive Moves (7/18/2025) SKBio Wins Chinese Clinical Trial Appro... (7/18/2025) China Releases 2nd Batch of Clinical Gui... (7/18/2025) China Seeks Comments on 96th Batch of Re... (7/18/2025) China Unveils New Clinical Trial Guideli... (7/18/2025) China Issues New Draft Guidelines for Ph... (7/18/2025) Hengrui's SHR‑A1904 Emerges as Promisin... (7/18/2025) China Approves First Homegrown Oral Anti... (7/18/2025) China Greenlights New Semaglutide Indica... (7/18/2025) China Approves Nation's First Recombinan... (7/18/2025) Novartis CEO Highlights China Momentum i... (7/18/2025) CMS Launches Secondary Listing in Singap... (7/18/2025) China Resources Pharma Plans CNY1B Innov... (7/18/2025) China Launches 11th Round of VBP, Coveri... (7/18/2025) Chinese Biotechs Drive Hong Kong IPO Boo... (7/18/2025) I‑Mab Deepens Bet on CLDN18.2 Bispecifi... (7/17/2025) VivaVision Secures New CNY 140M Series ... (7/17/2025) China Accepts Amgen and ONC Marketing Su... (7/17/2025)

China Hospitals Prioritize Local Innovation, Digital He... China's Pharma Market Faces Mixed Performance in Q1 202... China's Retail Pharmacy Market Hits CNY 941.1B in 2024 ... NH's DB6: China's Consumer Healthcare Market Underperfo... China's Hospital Drug Market Shows Slight Growth in 202...

Chinese Biotechs Drive Hong Kong IPO Boom in H12025 China Resources Pharma Plans CNY1B Innovation Fund to B... CMS Launches Secondary Listing in Singapore to Fuel Reg... Novartis CEO Highlights China Momentum in Q2 2025 Earni... VivaVision Secures New CNY 140M Series D2+ Round

China Issues New Draft Guidelines for Pharmaceutical De... China Unveils New Clinical Trial Guidelines for Antibac... China Seeks Comments on 96th Batch of Reference Formula... FDA Loosens Global Trial Standards but Keeps a Cautious... China Unveils New Atopic Dermatitis Guidelines and JAK1...

China Launches 11th Round of VBP, Covering 55 Medicines... China Releases 2nd Batch of Clinical Guidelines for Rar... China 2024 Healthcare Insurance Report: Milestones in C... China Issues 2nd Batch of Rare Disease Clinical Guideli... China's NHSA Unveils 2025 Drug Directory Revisions and ...

U.S. Lawmakers Raise Fresh Alarm Over GenScript's China... Record China Pharma Monopoly Fine Sends Strong Deterren... Conjupro Files USPTO Challenge on Ascletis' U.S. Patent... China's Draft National Medical Security Law: Seven Key ... China Releases Draft Medical Security Law for Public Co...

China Struggles to Maintain Grip on India's Bulk Drug M... API China 2025 Ends with High Attendance and Global Ind... FDA Issues Warning Letters to Two Chinese API Manufactu... Implications of China's Growing Influence in Global Pha... FDA Issues Warning to Tianjin Darentang for Manufacturi...

China Approves Nation's First Recombinant Human Albumin... China Greenlights New Semaglutide Indication to Combat ... China Approves First Homegrown Oral Anti‑Influenza Dru... Hengrui's SHR‑A1904 Emerges as Promising New Weapon Ag... SKBio Wins Chinese Clinical Trial Approval for GBP410

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Recent Executive Moves Astellas Pharma Executive Sentenced to 3½ Years in Chi... Recent Official and Executive Moves Recent Official and Executive Moves Recent Executive Moves

China Introduces Plan for Pudong New Area's Pilot Compr... Upcoming Event: 2023 Pharma CI USA Conference & Exhibit... Upcoming Event: 15th Annual Pharma Market Research Conf... Upcoming Event: 6th International Conference on Emergin... Upcoming Event: PHARM Connect Congress

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

2023 Order Form + Product Descripti... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu...